West Pharmaceutical Services (WST) Receivables - Net (2009 - 2026)

West Pharmaceutical Services has disclosed Receivables - Net across 18 years of filings, most recently posting $685.6 million for Q1 2026.

• Receivables - Net for Q1 2026 came in at $685.6 million, up 26.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $685.6 million (up 26.12% YoY), and the FY2025 annual result was $574.4 million, up 3.96% from the prior year.
• Receivables - Net came in at $685.6 million for Q1 2026 at West Pharmaceutical Services, up from $574.4 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $685.6 million in Q1 2026 to a low of $479.4 million in Q2 2024.
• The 5-year median for Receivables - Net is $524.3 million (2024), against an average of $540.6 million.
• Across the five-year window, Receivables - Net dropped 10.29% in 2024 and climbed 26.12% in 2026, its largest moves.
• West Pharmaceutical Services' Receivables - Net stood at $507.4 million in 2022, then grew by 0.91% to $512.0 million in 2023, then grew by 7.91% to $552.5 million in 2024, then rose by 3.96% to $574.4 million in 2025, then grew by 19.36% to $685.6 million in 2026.
• The last three Receivables - Net figures came in at $685.6 million (Q1 2026), $574.4 million (Q4 2025), and $625.0 million (Q3 2025), per Business Quant data.